Methylthioninium chloride controlled-release tablet - Cosmo Pharmaceuticals

Drug Profile

Methylthioninium chloride controlled-release tablet - Cosmo Pharmaceuticals

Alternative Names: CB-17-01; LuMeBlue; Methylene blue delayed-release - Cosmo; Methylene Blue MMX; Methylene blue MMX®; Methylene blue tablet - Cosmo

Latest Information Update: 30 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cosmo Pharmaceuticals
  • Class Diagnostic agents; Dimethylamines; Phenothiazines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Colorectal cancer

Most Recent Events

  • 23 May 2018 Cosmo Pharmaceuticals receives a Complete Response Letter from the US FDA regarding its submission of an NDA for Methylene Blue MMX™ for Colorectal cancer
  • 21 Mar 2018 Methylthioninium chloride controlled release tablet licensed to EA Pharma in Japan and South Korea
  • 01 Feb 2018 Methylthioninium chloride licensed to Pharmascience in Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top